Cascadian Therapeutics to Present at Jefferies 2017 Healthcare Conference

Loading...
Loading...

SEATTLE, May 31, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. CASC, a clinical-stage biopharmaceutical company, today announced that management will present at the Jefferies 2017 Healthcare Conference in New York on Tuesday, June 6, 2017, at 8:00 a.m. Eastern time / 5:00 a.m. Pacific time.

A live audio webcast of the presentation will be available through the "Events & Presentations" page of the "News & Events" section of Cascadian Therapeutics' website at www.cascadianrx.com. An archived edition of the session will be available later that day.

About Cascadian Therapeutics

Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. Its lead product candidate, tucatinib (also known as ONT-380) is an investigational oral, selective small molecule HER2 inhibitor. Cascadian Therapeutics is conducting a randomized, double-blind controlled pivotal clinical trial called HER2CLIMB, which is comparing tucatinib vs. placebo, each in combination with capecitabine and trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer with and without brain metastases, who have previously been treated with a taxane, trastuzumab, pertuzumab and T-DM1. Additional details on HER2CLIMB can be found at www.clinicaltrials.gov NCT or www.HER2CLIMB.com. For more information, please visit www.cascadianrx.com.

Investor and Media Contact:
Monique Greer
Cascadian Therapeutics
206-801-2107
mgreer@cascadianrx.com

Loading...
Loading...
Posted In: BiotechNewsPress ReleasesGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...